{
    "organizations": [],
    "uuid": "f74a8c6fcb2716ae5e94126cb0dbf3097b79a379",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-glaxosmithkline-receives-us-approv/brief-glaxosmithkline-receives-us-approval-of-arnuity-ellipta-for-use-in-children-from-5-years-old-who-suffer-from-asthma-idUSFWN1SS0PF",
    "ord_in_thread": 0,
    "title": "BRIEF-GlaxoSmithKline Receives US Approval Of Arnuity Ellipta For Use In Children From 5 Years Old Who Suffer From Asthma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 21 (Reuters) - GlaxoSmithKline PLC:\n* GSK RECEIVES US APPROVAL OF ARNUITY ELLIPTA FOR USE IN CHILDREN FROM 5 YEARS OLD WHO SUFFER FROM ASTHMA\n* RECEIVED APPROVAL FROM US FDA FOR USE OF ARNUITY ELLIPTA (FLUTICASONE FUROATE) FOR MAINTENANCE TREATMENT OF ASTHMA IN CHILDREN FROM AS YOUNG AS 5 YEARS Source: bit.ly/2KIfvII Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-05-22T00:03:00.000+03:00",
    "crawled": "2018-05-22T19:20:57.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "glaxosmithkline",
        "plc",
        "gsk",
        "receives",
        "u",
        "approval",
        "arnuity",
        "ellipta",
        "use",
        "child",
        "year",
        "old",
        "suffer",
        "asthma",
        "received",
        "approval",
        "u",
        "fda",
        "use",
        "arnuity",
        "ellipta",
        "fluticasone",
        "furoate",
        "maintenance",
        "treatment",
        "asthma",
        "child",
        "young",
        "year",
        "source",
        "company",
        "coverage"
    ]
}